首页> 美国卫生研究院文献>Transactions of the American Ophthalmological Society >The Influence of Genetics on Response to Treatment with Ranibizumab (Lucentis) for Age-Related Macular Degeneration: The Lucentis Genotype Study (An American Ophthalmological Society Thesis)
【2h】

The Influence of Genetics on Response to Treatment with Ranibizumab (Lucentis) for Age-Related Macular Degeneration: The Lucentis Genotype Study (An American Ophthalmological Society Thesis)

机译:遗传学对雷尼单抗(Lucentis)治疗与年龄相关的黄斑变性的反应的影响:Lucentis基因型研究(美国眼科学会论文)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

PurposeAge-related macular degeneration (AMD) has a complex etiology arising from genetic and environmental influences. This past decade have seen several genes associated with the disease. Variants in five genes have been confirmed to play a major role. The objective of this study was to evaluate whether genes influence treatment response to ranibizumab for neovascular AMD. The hypothesis was that an individual’s genetic variation will determine treatment response.
机译:目的与年龄相关的黄斑变性(AMD)具有复杂的病因,原因是遗传和环境影响。在过去的十年中,已经看到了几种与该疾病有关的基因。已经证实五个基因的变体起主要作用。本研究的目的是评估基因是否影响兰尼单抗对新生血管性AMD的治疗反应。假设是,个体的遗传变异将决定治疗反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号